Document Classification

Section Type: RESULTS

Text: The varenicline group had significantly higher continuous abstinence rates vs the placebo group during weeks 21 through 24 (37. 8 % for the varenicline group vs 12. 5 % for the placebo group ; RD, 25. 2 % [95 % CI, 21. 1 % -29. 4 %] ; RR, 3. 0 [95 % CI, 2. 4-3. 7]) and weeks 21 through 52 (27. 0 % for the varenicline group vs 9. 9 % for the placebo group ; RD, 17. 1 % [95 % CI, 13. 3 % -20. 9 %] ; RR, 2. 7 [95 % CI, 2. 1-3. 5]).